According to the International Tuberous Sclerosis Complex Consensus Conference 2012, mTOR inhibitors have been recommended as a first-line treatment to reduce the size of renal AMLs associated with TSC (Northrup et al. 2013). This evidence concerns the gene MTOR and tuberous sclerosis.